Aperture Sectors › Healthcare & Life Sciences › Precision medicine & genomics
Precision medicine & genomics funding
Precision medicine & genomics
A sub-sector of Healthcare & Life Sciences. Each company counts once, in its main sub-sector.
60 rounds, $2.3B raised by 52 companies, Jan 2, 2023 to Nov 14, 2026, 5% of Healthcare & Life Sciences capital. Top three companies: Mirador Therapeutics 28%, Colossal Biosciences 20%, Verily 13%.
| Company | HQ | Capital raised | Rounds | Exit |
|---|---|---|---|---|
| Mirador Therapeutics | United States | $650M | 2 | — |
| Colossal Biosciences | United States | $470M | 3 | — |
| Verily | United States | $300M | 1 | — |
| Caris Life Sciences | United States | $168M | 1 | — |
| Zephyr AI | United States | $111M | 1 | — |
| Character Biosciences | United States | $110M | 2 | — |
| GC Therapeutics | United States | $65M | 1 | — |
| Evvy | United States | $54M | 2 | — |
| Stylus Medicine | United States | $45M | 1 | — |
| ImpriMed | United States | $33M | 2 | — |
| Predicta Biosciences | United States | $29M | 2 | — |
| Amae Health | United States | $25M | 1 | — |
| Imagene AI | Israel | $23M | 1 | — |
| SeqOne | France | $23M | 1 | — |
| Betteromics | United States | $20M | 1 | — |
| One Biosciences | France | $17M | 1 | — |
| Hedera Dx | Switzerland | $17M | 1 | — |
| Aoming Xingcheng (奥明星程) | China | $15M | 1 | — |
| Junji Gene | China | $14M | 1 | — |
| Nucleus Genomics | United States | $14M | 1 | — |
| 4baseCare | India | $14M | 2 | — |
| Genialis | United States | $13M | 1 | — |
| Biostate AI | United States | $12M | 1 | — |
| Synthesize Bio | United States | $10M | 1 | — |
| Portrai | South Korea | $9.8M | 1 | — |
| Company | Amount | Stage | Announced |
|---|---|---|---|
| Mirador Therapeutics | $400M | Series A | Mar 21, 2024 |
| Verily | $300M | Unlabeled | Mar 19, 2026 |
| Mirador Therapeutics | $250M | Series B | Jan 12, 2026 |
| Colossal Biosciences | $200M | Series C | Jan 15, 2025 |
| Caris Life Sciences | $168M | Growth | Apr 7, 2025 |
| Colossal Biosciences | $150M | Series B | Jan 31, 2023 |
| Colossal Biosciences | $120M | Series C | Sep 19, 2025 |
| Zephyr AI | $111M | Series A | Mar 13, 2024 |
| Character Biosciences | $93M | Series B | Mar 26, 2025 |
| GC Therapeutics | $65M | Series A | Sep 19, 2024 |